PCSK9 inhibitors × lipids

TrialJAMA2014

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G Robinson et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2,067 people · 2014

Randomised comparison

Lowered lipids

−66.0percentage points−73.0 to −58.0

As reported

difference −66.0 %, 95% CI −73.0 to −58.0

One number in the abstract

the abstract, start to end

Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75%

← favours treatmentfavours comparator →
could be chance
Lipids
−66.0−73.0 to −58.0
StatinsPCSK9 inhibitorsLipids

PCSK9 inhibitors × lipidshelps?settled

unlikelylikely
0.930.93 without it

Statins × lipidshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

191 papers cite itlatest 60 shown

2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 24825642